Loading patent…
AssigneeKing Faisal University
InventorsMahmoud Kandeel Elsayed, Mizuki Yamamoto, Jin Gohda, Jun-Ichiro Inoue, Yasushi Kawaguchi, Hyung-Joo Kwon, Abdulla Al-Taher
Estimating the term…
Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.
An anti-SARS CoV-2 fusion peptide comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:
A pharmaceutical composition comprising an expression system encoding at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.